1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEBelizatinibCat. No.: HY-17603CAS No.: 1357920-84-3Synonyms: TSR-011分式: CHFNO分量: 577.73作靶點(diǎn): ALK; Trk Receptor作通路: Protein Tyrosine Kinase/RTK; Neuronal Signaling儲(chǔ)存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 mon

2、th溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 300 mg/mL (519.27 mM)* means soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲(chǔ)備液1 mM 1.7309 mL 8.6546 mL 17.3091 mL5 mM 0.3462 mL 1.7309 mL 3.4618 mL10 mM 0.1731 mL 0.8655 mL 1.7309 mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲(chǔ)備液，并請(qǐng)注意儲(chǔ)備液的保存式和期限。BIOLOGICAL ACTIVITY物活性 Bel

3、izatinib種有效的，可服的ALK 和 TRKA、TRKB、TRKC 雙重 抑制劑，對(duì)野型重 組 ALK 的 IC50 值為0.7 nM。IC50 & Target IC50: 0.7nM (ALK) 11/2 Master of Small Molecules 您邊的抑制劑師www.MedChemE體外研究 TSR-011 has antitumour activity in the clinical trials.體內(nèi)研究 TSR-011 exerts sustained potent inhibition of ALK-dependent tumour growth in mouse

4、 models 1.戶(hù)使本產(chǎn)品發(fā)表的科研獻(xiàn) J Pharm Biomed Anal. 2019 Apr 6;171:132-147.See more customer validations on HYPERLINK / www.MedChemEREFERENCES1. Sullivan I, et al. ALK inhibitors in non-small cell lung cancer: the latest evidence and developments. Ther Adv Med Oncol. 2016Jan;8(1):32-47.McePdfHeightCaution: Product has not been fully validated for medical applications.For research use only.Tel: 400-820-3792;Fax: 0